Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
Key Clinical Summary
- Population and Design: Phase 2 RedirecTT-1 trial evaluated talquetamab (GPRC5D-targeting) plus teclistamab (BCMA-targeting) in 90 patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease, a group with historically poor outcomes (median PFS 2 to 3 mo; OS 5 to 6 mo with standard care).
- Efficacy: With 17-month median follow-up, the combination achieved an ORR of ~80% and median PFS of 15 mo, with both DOR and OS not yet reached. Patients with low EMD tumor volume (<25 cm²) showed >90% response rates, indicating strong efficacy in lower-burden disease.
- Clinical Relevance: Dual bispecific antibody therapy (Tal + Tec) demonstrated markedly improved outcomes and durable responses versus historical benchmarks, supporting its potential as a transformative option for patients with EMD RRMM, and was simultaneously published in The New England Journal of Medicine.
Saad Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center, New York, New York, presented phase 2 results from the RedirecTT-1 trial, which evaluated the combination of teclistamab and talquetamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) with extramedullary disease (EMD) at the 2025 ASH Annual Meeting & Exposition.
The combination achieved an 80% overall response rate and a median progression-free survival of 15 months, far exceeding results seen with standard therapies or either agent alone.
Transcript:
Hello, my name is Saad Usmani. I'm the chief of the myeloma service at Memorial Sloan Kettering Cancer Center and I'm here at ASH in Orlando and I've recently shared the oral abstract titled RedirecTT-1. The focus really was on the phase 2 portion of the study, looking at extramedullary myeloma patients in the relapse refractory setting.
Extramedullary disease, or EMD, is a poor prognostic marker. It is biologically more aggressive, and the standard of care treatments don't work well for this particular subset of patients. The median PFS is expected to be about 2 to 3 months for standard of care treatments and the OS not more than 5 or 6 months. In this context, we know that teclistamab and talquetamab that target BCMA and GPRC5D are effective by specific antibodies. As single agents or monotherapies for EMD patients, they give us a median PFS of around 5 months or so individually.
The idea here was to combine them for this EMD patient population, a total of 90 patients were treated. The initial step-up dosing was given days 1 through 7. Between 2 to 4 days between dosing and then the full dose was given on an every 2-week basis. If patients were responding, you could extend that to every 4 weeks.
The results were quite remarkable, an overall response rate of about 80% with the median follow-up of around 17 months. The median PFS was 15 months. The duration of response at the 12-month mark has not been reached. OS still has not been reached for the overall population. We incorporated imaging, PET CT scan imaging from baseline and subsequent follow up in addition to the IMWG response criteria and actually looked at the tumor volume, EMD volume in patients, and found that those patients who had the lower volume less than 25 centimeters squared, their response rates were actually over 90%. So, quite remarkable results.
We are glad that we were able to present the study, and it actually had a simultaneous publication in The New England Journal of Medicine the same day.Thank you so much.
Source:
Usmani S, Kumar S, Mateos MV, et al. Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up. Dec 6-9, 2025; Orlando, FL. Abstract: 698
